Cellworks Study Supports Liquid Biopsy for Predicting Chemo-Immunotherapy Benefit in Advanced NSCLC
New findings indicate that liquid biopsy could enhance personalized treatment predictions for patients with advanced Non-Small Cell Lung Cancer (NSCLC) undergoing chemotherapy and immunotherapy.
New findings show potential for liquid biopsy to expand access to personalized treatment prediction in advanced NSCLC
SAN DIEGO, CA, UNITED STATES, April 22, 2026 /EINPresswire.com/ — Cellworks Group Inc., the leader in Personalized Therapy Solutions …